The estrous cycle moderates the food and body weight suppressive effects of glucagon‐like peptide‐1 receptor agonism
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70177 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Sarah V Applebey und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Estrous Cycle, Glucagon-Like Peptide-1 Receptor Agonists, Liraglutide, Weight Loss. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Aims
Emerging data suggest more young women than men are prescribed weight loss pharmacotherapies targeting the glucagon‐like peptide‐1 receptor (GLP‐1R). However, preclinical literature has largely used male animals to characterize the neural mechanisms underlying the weight loss abilities of GLP‐1R agonists (GLP‐1RAs), highlighting a need for female‐specific investigations. Recently, we described data pointing to the female estrous cycle as a possible moderator of GLP‐1RA's effects in rats. Expression of brainstem Glp1r and the GLP‐1 precursor gene, Gcg , increased during two estrous phases, proestrus and estrus (P/E), compared to males and compared to other phases, metestrus and diestrus (M/D). On this basis, we hypothesized that the weight‐reducing effects of GLP‐1RAs may be potentiated during P/E. Materials and Methods In separate experiments, we determined whether timing administration of acute liraglutide or chronic semaglutide to either P/E or M/D would moderate food intake and weight loss in female rats maintained on a high fat diet. We also used qPCR to explore estrous cycle‐dependent variation in Glp1r within widely distributed nuclei relevant to energy balance control.
Results
GLP‐1RA administration during P/E, compared to M/D, enhanced the intake‐suppressive effects of liraglutide and semaglutide. Moreover, semaglutide administered only during P/E led to greater body weight loss compared to M/D‐administered semaglutide. We also observed greater Glp1r expression in P/E compared to M/D in multiple nuclei.
Conclusions
GLP‐1RAs administered in P/E lead to significantly greater body weight loss via reduction in food intake. Collectively, these data may have translational implications for the timing of GLP‐1RA administration across the menstrual cycle.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
ORCID-Profile: Sarah V Applebey, Allison G Xiao, Benjamin C Reiner, Matthew R Hayes
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Applebey, S. V., Xiao, A. G., Reiner, B. C., & Hayes, M. R. (2026). The estrous cycle moderates the food and body weight suppressive effects of glucagon‐like peptide‐1 receptor agonism. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70177
Vancouver
Applebey SV, Xiao AG, Reiner BC, Hayes MR. The estrous cycle moderates the food and body weight suppressive effects of glucagon‐like peptide‐1 receptor agonism. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70177
BibTeX
@article{Applebey2026,
author = {Applebey, Sarah V and Xiao, Allison G and Reiner, Benjamin C and Hayes, Matthew R},
title = {The estrous cycle moderates the food and body weight suppressive effects of glucagon‐like peptide‐1 receptor agonism},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70177}
}
EUVIMED